Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma

ABSTRACT: Bortezomib therapy has been proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM). However, both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM Both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM. We found that down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.

ORGANISM(S): Homo sapiens

PROVIDER: GSE55818 | GEO | 2014/03/13

SECONDARY ACCESSION(S): PRJNA241067

REPOSITORIES: GEO